Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 0.77 |
| ▸ | FLT3 | P36888 | 18/20 | 0.77 |
| ▸ | KIT | P10721 | 16/20 | 0.77 |
| ▸ | CSF1R | P07333 | 9/20 | 0.77 |
| ▸ | FLT4 | P35916 | 9/20 | 0.77 |
| ▸ | FLT1 | P17948 | 8/20 | 0.77 |
| ▸ | LYN | P07948 | 7/20 | 0.77 |
| ▸ | SRC | P12931 | 6/20 | 0.77 |
| ▸ | BLK | P51451 | 6/20 | 0.77 |
| ▸ | PLK4 | O00444 | 5/20 | 0.77 |
| ▸ | AURKA | O14965 | 5/20 | 0.77 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.77 |
| ▸ | MET | P08581 | 5/20 | 0.77 |
| ▸ | PRKACA | P17612 | 5/20 | 0.77 |
| ▸ | RPS6KB1 | P23443 | 5/20 | 0.77 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.77 |
| ▸ | STK3 | Q13188 | 5/20 | 0.77 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.77 |
| ▸ | MARK2 | Q7KZI7 | 5/20 | 0.77 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1662335 | 0.88 | KDR (0.81) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL1659063 | 0.87 | KDR (0.79) | KDRFLT3KITCSF1RFLT4 | |
| Linifanib SCHEMBL93804 | 0.87 | KDR (1.00) | KDRFLT3KITCSF1RFLT4 | |
| Linifanib SCHEMBL29375368 | 0.87 | KDR (1.00) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL422778 | 0.86 | KDR (1.00) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL422640 | 0.86 | KDR (1.00) | KDRFLT3KITCSF1RFLT4 | |
| Linifanib SCHEMBL1880038 | 0.86 | KDR (0.98) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL423362 | 0.85 | KDR (1.00) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL421778 | 0.85 | KDR (1.00) | KDRFLT3KITCSF1RFLT4 | |
| SCHEMBL27825511 | 0.85 | KDR (0.88) | KDRFLT3KITCSF1RFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105245-A1 | METHODS FOR TREATING MACULAR EDEMA AND OCULAR ANGIOGENESIS USING AN ANTI-INFLAMMATORY AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | claimed |
| WO-2008080110-A1 | METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | ALCON, INC. (CH) | 2008-07-03 | — | — | WO | claimed |
| US-20080153818-A1 | preventing inflammation and retinal edema resulting from an ocular surgical procedure by administering to a patient undergoing surgery a therapeutically effective amount of a composition comprising an active agent selected from the group consisting of RTK inhibitors and anti-VEGF compounds | ALCON, INC. (CH) | 2008-06-26 | — | — | US | claimed |
| US-20070184089-A1 | Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use | ALCON, INC. (CH) | 2007-08-09 | — | — | US | claimed |
| EP-2594264-A1 | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective rtk inhibitors | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| EP-1850839-A2 | METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS | ALCON INC. (CH) | 2007-11-07 | — | — | EP | disclosed |
| US-20070184089-A1 | Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use | ALCON, INC. (CH) | 2007-08-09 | — | — | US | disclosed |
| WO-2006091801-A2 | METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS | ALCON, INC. (CH) | 2006-08-31 | — | — | WO | disclosed |
| US-20060189608-A1 | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors | ALCON, INC. | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070184089-A1 | Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use | NONO, ABCG2, PDE6C | KDR 428/4885FLT3 1749/4885KIT 2319/4885 |
| US-20090105245-A1 | METHODS FOR TREATING MACULAR EDEMA AND OCULAR ANGIOGENESIS USING AN ANTI-INFLAMMATORY AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | FLT1, TEK, FLT4 | KDR 4/4885FLT3 165/4885KIT 70/4885 |
| US-20060189608-A1 | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors | KDR, FLT4, FLT1 | KDR 1/4885FLT3 34/4885KIT 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.